f 12 media Search Results


paclitaxel  (Chem Impex International)
95
Chem Impex International paclitaxel
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
Paclitaxel, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/f+12+media/Paclitaxel/pmc07596148-84-17-21
Average 95 stars, based on 1 article reviews
paclitaxel - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
erythromycin  (Chem Impex International)
95
Chem Impex International erythromycin
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
Erythromycin, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/f+12+media/Erythromycin/10__1128_slash_aac__02360___18-138-24-37
Average 95 stars, based on 1 article reviews
erythromycin - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
dmem/ham’s f-12 media  (Vitrocell Systems GmbH)
90
Vitrocell Systems GmbH dmem/ham’s f-12 media
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
Dmem/Ham’s F 12 Media, supplied by Vitrocell Systems GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/f+12+media/dmem+ham%E2%80%99s+f+12+media/pmc11360456-61-8-11
Average 90 stars, based on 1 article reviews
dmem/ham’s f-12 media - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
hams f10 medium  (Corning Life Sciences)
90
Corning Life Sciences hams f10 medium
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
Hams F10 Medium, supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/f+12+media/hams+f+12+media/pmc05790179-624-5-9
Average 90 stars, based on 1 article reviews
hams f10 medium - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
ham’s f12 media  (HiMedia Laboratories)
90
HiMedia Laboratories ham’s f12 media
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
Ham’s F12 Media, supplied by HiMedia Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/f+12+media/ham%E2%80%99s+f+12+media/pmc06879320-327-12-14
Average 90 stars, based on 1 article reviews
ham’s f12 media - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
basal cell culture liquid media–dmem and ham’s f-12, 50/50 mix  (Corning Life Sciences)
90
Corning Life Sciences basal cell culture liquid media–dmem and ham’s f-12, 50/50 mix
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
Basal Cell Culture Liquid Media–Dmem And Ham’s F 12, 50/50 Mix, supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/f+12+media/basal+cell+culture+liquid+media+dmem+and+ham+s+f+12/pmc09371974-283-15-7
Average 90 stars, based on 1 article reviews
basal cell culture liquid media–dmem and ham’s f-12, 50/50 mix - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
selection media f-12 plus hygromycin  (BioShop)
90
BioShop selection media f-12 plus hygromycin
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
Selection Media F 12 Plus Hygromycin, supplied by BioShop, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/f+12+media/selection+media+f+12+plus+hygromycin/10__1074_slash_jbc__m407887200-84-19-26
Average 90 stars, based on 1 article reviews
selection media f-12 plus hygromycin - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
dmem (dulbecco’s modified eagle’s medium) /hams f-12 50/50 mix media (cat # 16-405-cv)  (Corning Life Sciences)
90
Corning Life Sciences dmem (dulbecco’s modified eagle’s medium) /hams f-12 50/50 mix media (cat # 16-405-cv)
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
Dmem (Dulbecco’s Modified Eagle’s Medium) /Hams F 12 50/50 Mix Media (Cat # 16 405 Cv), supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/f+12+media/DMEM++Dulbecco%E2%80%99s+Modified+Eagle%E2%80%99s+Medium+++Hams+F+12+50+50+mix+media++Cat+++16+405+CV/pmc06905550-115-8-8
Average 90 stars, based on 1 article reviews
dmem (dulbecco’s modified eagle’s medium) /hams f-12 50/50 mix media (cat # 16-405-cv) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
cellfree dmem/f-12 media (0.8 ml)  (Becton Dickinson)
90
Becton Dickinson cellfree dmem/f-12 media (0.8 ml)
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
Cellfree Dmem/F 12 Media (0.8 Ml), supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/f+12+media/cellfree+dmem+f+12+media++0+8+ml+/us11833191-209-0-11
Average 90 stars, based on 1 article reviews
cellfree dmem/f-12 media (0.8 ml) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
dulbecco’s modified eagle medium and ham’s f-12 media  (Corning Life Sciences)
90
Corning Life Sciences dulbecco’s modified eagle medium and ham’s f-12 media
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
Dulbecco’s Modified Eagle Medium And Ham’s F 12 Media, supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/f+12+media/dulbecco%E2%80%99s+modified+eagle+medium+and+ham%E2%80%99s+f+12+media/pmc10589850-374-18-20
Average 90 stars, based on 1 article reviews
dulbecco’s modified eagle medium and ham’s f-12 media - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
f-12 media  (Avantor)
90
Avantor f-12 media
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
F 12 Media, supplied by Avantor, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/f+12+media/f+12+media/pm36746947-270-37-42
Average 90 stars, based on 1 article reviews
f-12 media - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
organoind media dmem/f-12 with hepes stemcell 36254  (STEMCELL Technologies Inc)
90
STEMCELL Technologies Inc organoind media dmem/f-12 with hepes stemcell 36254
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
Organoind Media Dmem/F 12 With Hepes Stemcell 36254, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/f+12+media/organoind+media+dmem+f+12+with+hepes+stemcell+36254/us12336988-116-12-19
Average 90 stars, based on 1 article reviews
organoind media dmem/f-12 with hepes stemcell 36254 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), Paclitaxel (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.

Journal: Cellular and Molecular Bioengineering

Article Title: Re-engineering Antimicrobial Peptides into Oncolytics Targeting Drug-Resistant Ovarian Cancers

doi: 10.1007/s12195-020-00626-z

Figure Lengend Snippet: Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), Paclitaxel (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.

Article Snippet: 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), Fmoc-protected amino acids, N,N 0 -diisopropylcarbodiimide (DIC), O-(7-Azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate (HATU), N,N -dimethylformamide (DMF), and Paclitaxel were purchased from Chem-Impex International, Inc. RPMI-1640, M199, trypsin and EDTA solution, Antibiotic-Antimycotic Solution, ultra-low attachment (ULA) plates, and 1× phosphate buffered saline (PBS) were purchased from Corning.

Techniques: Concentration Assay, Comparison, Activity Assay, Derivative Assay, Cell Culture